Thermo Fisher Scientific Reports 9% Revenue Growth as Third-Quarter Earnings Beat Estimates

Thermo Fisher Scientific (TMO) reported Q3 revenue growth across most segments, with Life Sciences up 5%, Analytical Instruments up 6%, and Lab Products up 15%. Specialty Diagnostics saw a 6% revenue decline. Adjusted operating margins improved in all segments. The company introduced AI-enabled products and raised its 2026 revenue and EPS guidance to $47.7B-$48.2B and $25.13-$25.43, respectively. It also completed the divestiture of its microbiology business and repaid $1.1B in senior notes.

Thermo Fisher Scientific (TMO) reported Q3 2026 earnings of $6.68 per share, up 15% YoY, and revenues of $12.14B, up 9% YoY, both beating estimates. Despite strong results, TMO stock fell 4.1% in pre-market trading. The company saw growth in most segments except Specialty Diagnostics, which declined 6.5%. Adjusted operating margin widened to 24.5%. TMO also announced strategic partnerships and new product launches. The company plans to provide updated full-year guidance on Oct. 21.

Thermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with adjusted EPS rising 15% to $6.68. Organic growth was 6%, and margins improved. The company launched new products, partnered with Mayo Clinic, and opened new facilities. GAAP EPS increased 9% to $4.64. Shares fell 2% premarket.

Thermo Fisher Scientific (TMO) shares are down 2.5% pre-market despite beating Q3 earnings estimates (EPS: $6.68 vs $6.40, revenue: $12.14B vs $11.95B). While Laboratory Products and Biopharma Services grew 15%, Life Sciences Solutions and Specialty Diagnostics underperformed. The stock's high valuation and insider selling add to pressure. Analysts had recently raised price targets, potentially front-loading gains. Investors await 2026 guidance for further direction.

Thermo Fisher Scientific (TMO) shares rose premarket after Q3 2026 earnings beat expectations, reporting $12.1B revenue and $6.68 EPS. Growth was driven by the Laboratory Products and Biopharma Services segment, while other segments underperformed. The company's GF Score is 84/100, indicating strong financial health, but it is modestly overvalued according to GF Value.

Thermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with net income rising 6.2% to $1.721B. Adjusted EPS grew 15% to $6.68. Life Sciences and Analytical Instruments revenues increased, while Specialty Diagnostics declined. The company launched new products and facilities, and will update 2026 guidance during its earnings call.